

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
10 February 2024 :: Issue 737
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



[Strategic Advisory Group of Experts on Immunization \(SAGE\) - March 2024](#)

11 – 14 March 2024 Geneva

[Draft agenda](#)

- Global and regional reports – Session 1
- IA2030 deep dive – Session 2
- Polio – Session 3
- Hepatitis E – Session 4
- COVID-19 – Session 5
- Mpox – Session 6
- Immune correlates – Session 7
- RSV – Session 8



Malaria

[Nearly 10 000 children vaccinated as malaria vaccine rollout in Africa expands](#)

09 February 2024

Brazzaville – Nearly 10 000 children in Burkina Faso and Cameroon have now received the RTS,S malaria vaccine since being introduced this year. A wider malaria vaccine rollout is underway this year in several African countries, with Cameroon being the first outside the malaria vaccine pilot programme to do so.

Cameroon launched the vaccine on 22 January 2024. It is being integrated into its national routine immunization programme in more than 500 public and private health facilities across 42 health districts in the country's 10 regions.

Burkina Faso introduced the vaccine on 5 February, becoming the latest country in the region to kick off the immunization. The game-changing vaccine complements the existing range of malaria control measures to prevent the disease and lower its burden.

“Malaria is one of the major health challenges our region faces. The wider rollout of the malaria vaccine marks a significant milestone in advancing the fight against this deadly disease,” said Dr Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa. “We’re committed to supporting countries to ensure that all eligible children are protected from the devastating impacts of this preventable illness.”

The vaccine rollout in the two countries mark the start of a major initiative by the WHO Regional Office for Africa's Accelerated Malaria Vaccines Introduction and Rollout in Africa (AMVIRA)...



Featured Journal Content

Vaccine

Volume 42, Issue 4 Pages 723-994 (6 February 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/4>

Research article Abstract only

[Expanding polio surveillance reach beyond vaccination reach in Borno State, Nigeria: The contribution of community informants from insecure areas engaged to conduct polio surveillance in security compromised areas, 2018–2019](#)

Abede Momoh Mohammed, Audu Musa, Sume Gerald Etapelong, Mohammed Tahir Bolori, ... Walter Kazadi Mulombo

Pages 770-776

Abstract

Introduction

Borno state in north-eastern Nigeria is the epicentre of the >10 years' insurgency activities that have affected the region since 2009, resulting in the destruction of health facilities, killing of health workers, massive population displacement and lack of access to populations to provide health services. This article demonstrates how the involvement of community informants from insecure areas (CIIA) to conduct polio surveillance in security-challenged settlements of Borno state contributed to the expansion of polio surveillance reach beyond polio vaccination reach.

Method

In each of the 19 security compromised Local Government areas (LGAs) with community informants from insecure areas, Android phones enabled with Vaccination Tracking System (VTS) technology and Open Data Kit (ODK) mobile application were provided to capture geo-coordinates as evidence (geo evidence) for polio surveillance activity conducted. These geo evidence captured were uploaded and mapped to show insecure settlements reached with polio surveillance and those yet to be reached.

Results

A total of 3183 security compromised settlements were reached for polio surveillance between March 2018 and October 2019 with valid geo evidence, 542 of these security-compromised settlements had not been previously reached by any other intervention for polio surveillance or polio vaccination.

Conclusion

The capturing of geo-coordinates as a proxy indicator of polio surveillance activity conducted by informants provided significant evidence of settlements reached for sustained polio surveillance even when a case of Acute Flaccid Paralysis (AFP) had not been reported from these settlements. Using the geo evidence captured by CIIA in insecure settlements, we have demonstrated the expansion of polio surveillance reach beyond polio vaccination reach in Borno state.

.....

.....

Featured Journal Content

PLoS One

<http://www.plosone.org/>

[Accessed 10 Feb 2024]

[High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study](#)

María Inés Sarmiento-Medina, Miryam Puerto de Amaya, Licet Villamizar-Gómez, Andrea Carolina González-Coba, Laura Guzmán-Barajas

Research Article | published 05 Feb 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0297579>

Abstract

Cervical cancer, primarily caused by Human Papillomavirus (HPV) transmission through sexual contact, necessitates comprehensive strategies to combat its impact on women's health. Yet, certain underserved populations, such as low socioeconomic and ethnic minority groups, encounter barriers in accessing timely interventions and early diagnosis. This cross-sectional study was conducted with the aim of assessing HPV prevalence, genotype distribution, and co-infections among 280 adult women residing in a Colombian Indigenous Reserve within the Amazon region.

The research adhered to a community-centric approach that respected cultural norms, native languages, and Indigenous authorities' permission. The study revealed an overall HPV infection prevalence of 31.1% ($n = 87$, 95% CI 25.7–36.8), with 22.5% ($n = 63$, 95% CI 17.7–27.8) of women infected by at least one high-risk HPV genotype and 15.0% ($n = 42$, 95% CI 11–19.7) infected by at least one LR genotype. These results align with the findings of other Colombian studies. Notable high-frequency genotypes included 16, 52, 66, 56, and 68, with the most common combinations being [66–52] and [66–58].

The study also assessed the prevalence of HPV vaccination, revealing a rate of 22.9%, lower than the national average. In vaccinated women, the prevalence of genotypes 16 and 18 was significantly reduced, as anticipated. Importantly, it was observed that 57.1% of all high-risk HPV infections could have been prevented with the use of the nonavalent vaccine.

These findings underscore the critical need to enhance adherence to early cervical cancer detection and monitor positive cases to evaluate high-risk HPV persistence. Efforts should be directed toward continuing vaccination coverage against high-risk HPV 16 and 18 with the quadrivalent vaccine, while also striving to make the nonavalent vaccine accessible for inclusion in large-scale public health programs. Additionally, the study did not identify a specific pattern of co-infection. The study emphasizes the significance of adopting a locally tailored epidemiological approach to guide and promote cervical cancer prevention efforts in Indigenous communities.



Featured Journal Content

[Pathogen genomics and One Health: a scoping review of current practices in zoonotic disease research](#)

Stefano Catalano, Francesca Battelli, Zoumana I Traore, Jayna Raghvani, Christina L Faust, Claire J Standley

medRxiv 2024.02.05.24302264; doi: <https://doi.org/10.1101/2024.02.05.24302264>

ABSTRACT

Whole-genome sequencing has revolutionised the field of infectious disease surveillance, enabling near real-time detection of pathogens and tracking how infections may spread. We performed a scoping review of studies that have applied genomic epidemiology to zoonotic disease transmission across One Health domains (human, animal, and environment). We identified 114 records published between 2005 and 2022 which reported original multi-domain genomic data of zoonotic pathogens integrated into phylogenetic models. Most studies investigated bacterial pathogens, highlighting key knowledge gaps for other zoonotic agents, particularly arboviruses. Sampling and sequencing efforts vastly varied across domains: the median number and range of pathogen genomes analysed were highest for humans (23; 1-29,586) and lowest for the environment domain (13; 1-956). Infectious disease genomics was leveraged to track zoonotic disease outbreaks and cross-domain transmission, to enhance pathogen surveillance, and to disentangle evolutionary dynamics driving lineage diversification and virulence. Our study informs effective study design for future genomic applications to multi-domain and cross-species transmission of zoonoses, with the potential to identify key infection sources and inform interventions for local and global health security.

Funding Statement

SC, FB, ZIT, and CJS were sponsored by the Defense Threat Reduction Agency, United States Department of the Defense (HDTRA12110028). The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. CLF was supported by a Natural Environment Research Council Independent Research Fellowship (NE/V01430/1). JR was supported by the UK Research and Innovation Global Challenges Research Fund One Health Poultry Hub (BB/S011269/1).

.....
.....
.....

Polio – PHEIC

Polio this week as of 07 Feb 2024 - GPEI

Headlines

:: Integration involves using polio tools, staff, expertise, and other resources to deliver important health interventions alongside polio vaccines – from measles vaccines and other essential immunizations to birth registration, counselling on breastfeeding, hand soap and more. It also includes incorporating polio vaccines into other planned health interventions when possible, delivering more services with fewer resources. [Read more...](#)

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 30 WPV1-positive environmental samples
- Chad: one cVDPV2 case
- Côte d'Ivoire: two cVDPV2-positive environmental samples
- DR Congo: one cVDPV2 positive environmental sample
- Egypt: two cVDPV2 positive environmental samples
- Nigeria: three cVDPV2 cases and six positive environmental samples
- Zimbabwe: three cVDPV2-positive environmental samples

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

WHO & Regional Offices [to 10 Feb 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

11 February 2024 Highlights

WHO Medically Important Antimicrobial List 2024

9 February 2024 Departmental news

[Digital payments to health workers boost retention, motivation, and impact](#)

7 February 2024 Departmental news

[European Medicines Agency \(EMA\) adopts a positive scientific opinion on arPraziquantel](#)

6 February 2024 Departmental news

[WHO reports outline responses to cyber-attacks on health care and the rise of disinformation in public health emergencies](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 09 February 2024

[Nearly 10 000 children vaccinated as malaria vaccine rollout in Africa expands](#)

WHO Region of the Americas PAHO

[:: PAHO, WHO directors meet President Lula to discuss priority health issues for Brazil, the Americas and the world](#)

Brasilia, February 7, 2024 - On an official visit to Brazil, the Director of the Pan American Health Organization (PAHO), Jarbas Barbosa, and the Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, met on Monday 5 February with the President of the Republic of Brazil, Luiz Inácio Lula da Silva, and the country's...

[:: CEPI and PAHO collaborate to boost regional preparedness against diseases with epidemic or pandemic potential](#)

Oslo, Norway, Washington, D.C, USA, 6 February 2024 - The Coalition for Epidemic Preparedness Innovations (CEPI) and the Pan American Health Organization (PAHO) have signed a Memorandum of Understanding to strengthen collaboration between the two organisations as they strive to enhance regional epidemic and pandemic preparedness, and to...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

Website not responding at inquiry.

WHO Eastern Mediterranean Region EMRO

[:: WHO, KSrelief sign new agreement to support over one million people in Gaza](#)

6 February 2024, Cairo, Egypt – A US\$ 10 million agreement signed today by the World Health Organization (WHO) and the King Salman Humanitarian Aid and Relief Centre (KSrelief) will provide more than one million people in Gaza with access to emergency life-saving health services.

“The collaboration between WHO and KSrelief signifies a strategic, coordinated response to addressing urgent health needs in Gaza,” said Dr Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean. “KSrelief’s generous commitment will enable WHO to continue bolstering the health system, ensuring that people displaced by ongoing violence have access to lifesaving health care.”

The project, which will be implemented over a 12-month period, will support 30 primary health care centers and 10 hospitals and ambulances across Gaza with essential medicines, medical supplies and disposables, and fuel. Approximately one million internally displaced people and those living within the catchment area of the targeted health facilities stand to benefit from this project...

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[9 February 2024 | Influenza A\(H1N1\) variant virus - Spain](#)

[8 February 2024 | Western Equine Encephalitis - Uruguay](#)

[8 February 2024 | Avian Influenza A \(H5N1\) - Cambodia](#)

[7 February 2024 | Influenza A \(H1N1\) variant virus - Brazil](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 06, pp. 61–68 9 February 2024

<https://iris.who.int/bitstream/handle/10665/375928/WER9906-eng-fre.pdf>

:: 12th Meeting of the WHO Expert Working Group on Surveillance of Antiviral Susceptibility of Influenza Viruses for the WHO Global Influenza Surveillance and Response System

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

8 February 2024

[Workshop on strengthening laboratory services for antimicrobial resistance \(AMR\) surveillance in leprosy,...](#)

7 February 2024

[Guidance on establishing national and local AMR surveillance systems in the Western Pacific Region](#)

7 February 2024

[Digital adaptation kit for HIV, second edition](#)

5 February 2024

[Joint external evaluation of IHR core capacities of Azerbaijan](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

[Readout of HHS Secretary Becerra's Meeting with Pharmacy CEOs on COVID-19 Therapeutics Commercialization](#)

February 7, 2024 News Release

[HHS Releases the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People](#)

February 6, 2024 News Release

17 federal departments and agencies developed an interagency plan to combat vector-borne diseases

Today, the U.S. Department of Health and Human Services released the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People (VBD National Strategy). As directed by the 2019 Kay Hagan Tick Act—named after the U.S. Senator who died due to complications from a tickborne illness—HHS led a four-year process with civilian agencies and defense departments to deliver this strategy. Co-led by the HHS Office of the Assistant Secretary for Health and the Centers for Disease Control and Prevention, the strategy identifies and describes federal priorities to detect, prevent, respond to, and control diseases and conditions caused by vectors in the United States.

This VBD National Strategy represents the largest formal federal coordination effort focused on vector-borne disease prevention and control with contributions by over 50 representatives across 17 federal agencies. This collaborative effort will help

:: Address the significant public health challenges related to vector-borne diseases;

:: Incorporate a One Health approach to enhance coordination and communication across human, animal, and environmental areas; and

:: Reverse the upward trends in illness, suffering, and death...

FDA

Press Announcements

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement](#) - 03/05/2024

CDC/ACIP [U.S.] [to 10 Feb 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

[CDC Opens New East Asia and Pacific Regional Office in Japan](#)

February 5, 2024 TOKYO, February 5, 2024 – U.S. Centers for Disease Control and Prevention (CDC) Director Mandy Cohen celebrated the opening of the new CDC East Asia and Pacific (EAP) regional office in Tokyo, Japan, at a ceremony that included U.S.

ACIP Meetings

Next ACIP Meeting

February 28-29

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

February 8, 2024 / No. 5

[PDF of this issue](#)

- Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance — United States, 2024

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 February 2024

Paxlovid: reminder of serious adverse reactions when taken together with certain immunosuppressants

9 February 2024

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

No new digest content identified.

.....
.....

Africa CDC [to 10 Feb 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

No new digest content identified.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 10 Feb 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 10 Feb 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-02-09 / No. 6

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 10 Feb 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 10 Feb 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 10 Feb 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 10 Feb 2024]

<https://carb-x.org/>

News

02.08.2024 |

[CARB-X funds Visby Medical to develop a portable rapid diagnostic for gonorrhea including antibiotic susceptibility](#)

CARB-X will award up to US\$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhoea, *Neisseria gonorrhoeae* (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

CEPI – Coalition for Epidemic Preparedness Innovations [to 10 Feb 2024]

<http://cepi.net/>

Latest News

Plant-based ALiCE® technology could shave weeks off vaccine production

With CEPI funding, researchers at LenioBio will test if their cell-free technology can produce vaccine proteins in as little as 20 days.

News 08 Feb 2024

Regionalizing vaccine manufacturing: a path to equitable access

Dr. Frederik Kristensen, Inaugural Managing Director of the Regionalized Vaccine Manufacturing Collaborative and former Deputy CEO of CEPI, reinforces the need for regionalised vaccine manufacturing as a path forward to better equity

Blog 07 Feb 2024

CEPI and PAHO collaborate to boost regional preparedness against diseases with epidemic or pandemic potential

CEPI and PAHO have signed a Memorandum of Understanding to strengthen collaboration between the two organisations as they strive to enhance regional epidemic and pandemic preparedness.

News 06 Feb 2024

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 10 Feb 2024]

<https://cioms.ch/>

News; Publications; Events

CIOMS Glossary of ICH terms and definitions: Version 5 now available

Version 5 of the CIOMS Glossary of ICH terms and definitions is now freely available [here](#). It can also be accessed from the ICH webpage [here](#).

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 10 Feb 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 10 Feb 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 10 Feb 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 10 Feb 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 10 Feb 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 10 Feb 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[Community well-being and climate change](#)

Added February 7, 2024

[Knowledge, experiences, and access to sexual and reproductive health services among refugee, migrant, or displaced girls and women in Africa](#)

Added February 5, 2024

Fondation Merieux [to 10 Feb 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 10 Feb 2024]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GE2P2 Global Foundation [to 10 Feb 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – February 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 09 January 2024 – Issue 12](#)

GHIT Fund [to 10 Feb 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 10 Feb 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 10 Feb 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 10 Feb 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 10 Feb 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 10 Feb 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 10 Feb 2024]

<https://www.iavi.org/>

News, Features

Features

[Championing domestic financing to promote a vibrant vaccine research and development enterprise in Africa](#)

February 7, 2024

Advocating for financing for vaccine and health research, development, and innovation for Africa by Africa.

INSERM [to 10 Feb 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 10 Feb 2024]

<https://www.ich.org/page/press-releases>
News/Pubs/Press Releases [Selective]
No new digest content identified.

ICRC [to 10 Feb 2024]

<https://www.icrc.org/en/whats-new>
What's New [Selected]
No new digest content identified.

IFFIm

<http://www.iffim.org/>
Press Releases/Announcements
No new digest content identified.

IFRC [to 10 Feb 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 10 Feb 2024]

<https://www.pasteur.fr/en/press-area>
Press Documents
No new digest content identified.

ISC / International Science Council [to 10 Feb 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

[International Day of Women and Girls in Science](#)

Despite progress in women's education, a persistent gender gap exists across all levels of science, technology, engineering, and mathematics (STEM) globally.

08.02.2024

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 10 Feb 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events
No new digest content identified.

IVI [to 10 Feb 2024]
<http://www.ivi.int/>
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 10 Feb 2024]
<https://centerforhealthsecurity.org/newsroom>
Center News [Selected]
February 06:
[**Johns Hopkins Center for Health Security responds to NIST RFI on Implementing the Artificial Intelligence Executive Order to Guard Against High-Consequence Bio Risks**](#)

MSF/Médecins Sans Frontières [to 10 Feb 2024]
<http://www.msf.org/>
Latest [Selected Announcements]
Haemorrhagic fevers
[**Vaccination halves mortality among people infected with Ebola**](#)
Press Release 8 Feb 2024

Paris – An observational study conducted by Epicentre, Médecins Sans Frontières' (MSF) medical research and epidemiology centre, the results of which are published in The Lancet Infectious Diseases, shows for the first time that vaccination can halve mortality among people infected by [Ebola...](#)

Gaza-Israel war
[**Lack of clean water brings disease and suffering in Gaza**](#)
Project Update 8 Feb 2024

National Academy of Medicine - USA [to 10 Feb 2024]
<https://nam.edu/programs/>
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 10 Feb 2024]
<https://www.nationalacademies.org/newsroom?>
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 10 Feb 2024]
<https://www.hhs.gov/vaccines/about/index.html>
Upcoming Meetings/Latest Updates
February 22-23, 2024 (Virtual)

NIH [to 10 Feb 2024]

<http://www.nih.gov/>

News Releases

No new digest content identified.

PATH [to 10 Feb 2024]

<https://www.path.org/media-center/>

Newsroom

[PATH statement on the continuing violence in Israel, Gaza, and the West Bank](#)

February 6, 2024 by PATH

Rockefeller Foundation [to 10 Feb 2024]

<https://www.rockefellerfoundation.org/>

News and Announcements

[The Rockefeller Foundation Supports Innovation Institute for Food and Health and Periodic Table of Food Initiative Collaboration for Improving Understanding of Agricultural Sustainability Practices on](#)

Press Releases Published Date February 08, 2024

Sabin Vaccine Institute [to 10 Feb 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 10 Feb 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

No new digest content identified.

UNICEF [to 10 Feb 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Statement 09 February 2024

[Statement by UNICEF Executive Director Catherine Russell on Rafah, Gaza](#)

<https://www.unicef.org/press-releases/statement-unicef-executive-director-catherine-russell-rafah-gaza>

NEW YORK, 8 February 2024 – “UNICEF is urgently calling on the parties to refrain from military escalation in Rafah Governorate in Gaza where over 600,000 children and their families have been displaced – many of them more than once. “An escalation of the fighting in Rafah, which is already straining under the extraordinary number of people who...

Press release 08 February 2024

[Record numbers of children seek life-saving care as Sudan war drives world’s worst displacement crisis](#)

<https://www.unicef.org/press-releases/record-numbers-children-seek-life-saving-care-sudan-war-drives-worlds-worst>

PORT SUDAN, 9 February 2024 – As Sudan’s brutal war hits the 300-day mark, widespread malnutrition, the world’s largest child displacement crisis, and a shattered health system threaten to kill far more children than the armed conflict itself. UNICEF is seeing record levels of admissions for the treatment of severe acute malnutrition (SAM) – the...

Statement 08 February 2024

[UNICEF urges all parties to safeguard children amid latest unrest in Haiti](https://www.unicef.org/press-releases/unicef-urges-all-parties-safeguard-children-amid-latest-unrest-haiti)

<https://www.unicef.org/press-releases/unicef-urges-all-parties-safeguard-children-amid-latest-unrest-haiti>

PORT-AU-PRINCE, 8 February 2024 – UNICEF is deeply concerned by recent reports highlighting the violence faced and witnessed by children during the current socio-political events in Haiti. We urge all stakeholders to ensure that children are protected, regardless of their situation. Protecting children should be the priority. UNICEF calls on...

Press release 07 February 2024

[UNICEF strengthens response to DRC's worst floods in 60 years and growing cholera outbreak](https://www.unicef.org/press-releases/unicef-strengthens-response-drcs-worst-floods-60-years-and-growing-cholera-outbreak)

<https://www.unicef.org/press-releases/unicef-strengthens-response-drcs-worst-floods-60-years-and-growing-cholera-outbreak>

KINSHASA, Democratic Republic of the Congo, 7 February 2024 – UNICEF and partners are responding to devastating flooding in the Democratic Republic of the Congo (DRC), with the Congo River rising to levels not seen in more than 60 years. Eighteen out of DRC’s 26 provinces are affected following exceptionally heavy rainfall over the past couple of...

Unitaid [to 10 Feb 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 10 Feb 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 10 Feb 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 10 Feb 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 10 Feb 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

February 2024: Vaccines and Infectious Diseases in the News

Published on Feb 07, 2024

Find information about the latest vaccines and infectious diseases that have been in the news.

Measles

Cases of measles continued to be identified in Philadelphia and the surrounding area during January, and the Centers for Disease Control and Prevention (CDC) recently alerted healthcare providers across the country to monitor for measles.

Find out more about the current outbreaks:

[Deadly Decisions? February 1, 2024 Parents PACK](#)

[CDC alert to healthcare providers, January 25, 2024](#)

[Why are we seeing measles outbreaks? Video featuring Dr. Paul Offit, VEC Director](#)

To find out more about measles and the vaccine, check these VEC resources:

[Doctors Talk: Measles \(video\)](#)

[Measles: What You Should Know \(Q&A\) in English | Spanish | Japanese](#)

[Rash information \(webpage\)](#) — Go to “Measles – viral” section of page

[A Look at Each Vaccine: Measles, Mumps and Rubella \(MMR\) Vaccine \(webpage\)](#)

[MMR \(infographic\)](#)

[Parents PACK Personal stories: Measles](#)

Fall respiratory viruses (Influenza, COVID-19 and RSV)

It is not surprising that cases of three vaccine-preventable respiratory diseases (Influenza, COVID-19 and RSV) are increasing on the heels of holiday gatherings. When we spread our good cheer, we also share our viruses. While it is not too late to get vaccinated against any of these infections (the seasons for flu and RSV will go through the spring and COVID-19 has yet to become seasonal), remember that it takes about two weeks to gain immunity following vaccination.

[Find out more about each of these vaccines and who should get them in this video with Dr. Offit.](#)

You can also check our “Look at Each Vaccine” pages related to these viruses and the vaccines that prevent them:

[Influenza](#)

[COVID-19](#)

[RSV](#)

Misinformation about DNA fragments in COVID-19 mRNA vaccines

Recently, DNA fragments in COVID-19 mRNA vaccines have been a source for concern, particularly following unfounded statements during official proceedings or by political appointees. To be clear, the mRNA vaccines are safe and these concerns related to DNA fragments are unfounded.

[Watch this video in which Dr. Offit describes why we do not need to worry about this issue when it comes to mRNA vaccines.](#)

For additional information, please check these VEC webpages:

[COVIDVaccineAnswers.org](#)

[Vaccine Ingredients – DNA](#)

[You can also read more about the misinformation surrounding DNA fragments in Dr. Offit’s Substack, “Beyond the Noise.”](#)

Wellcome Trust [to 10 Feb 2024]

<https://wellcome.org/>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 10 Feb 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

World Bank [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 10 Feb 2024]

<https://www.wfpha.org/>

Blog

No new digest content identified.

World Medical Association [WMA] [to 10 Feb 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 10 Feb 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 10 Feb 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 10 Feb 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 10 Feb 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 10 Feb 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 10 Feb 2024]

<https://ifpma.org/>

Selected Press Releases/Statements

Statement 6 Feb 2024

[IFPMA statement ahead of the opening of the fourth WHO Fair Pricing Forum](#)

The fourth meeting of the WHO's Fair Pricing Forum represents an important opportunity to discuss how the global health community can work together to improve access to medicines and vaccines, deliver on the ambition of the Sustainable Development Goals (SDGs), and to achieve Universal Health Coverage (UHC) by 2030. IFPMA and our members continue to be committed to these goals and welcome the opportunity to share perspectives on how we can work together to achieve them.

Statement 5 Feb 2024

[7th Meeting of the Working Group on Amendments to the International Health Regulations \(2005\)](#)

On 5 February, IFPMA delivered a statement at the 7th Meeting of the Working Group on Amendments to the [International Health Regulations \(2005\)](#) in Geneva, Switzerland.

International Alliance of Patients' Organizations – IAPO [to 10 Feb 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 10 Feb 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified.*

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases

8 February 2024

[BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs](#)

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals - China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media

06 February 2024

[GSK's RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk](#)

GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.

06 February 2024

[GSK's regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration](#)

Shingrix already approved in China for adults aged 50 years and over.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases

February 7, 2024

[Respiratory Syncytial Virus \(RSV\): What You Need to Know](#)

February 7, 2024

[Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering](#)

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases

[Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a \\$15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities](#)

Monday, February 05, 2024

The initiative, "Change the Odds: Uniting to Improve Cancer Outcomes™" aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified [English translation function not operating]

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified

Valneva

[Press Releases](#) - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

[Home](#) - Website not responding [404 error]

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 2: E97-194 Feb 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Health Ecology and Disease Transmission

About 75% of emerging infectious diseases are now zoonotic, with continued climate change expected to exacerbate transmission in environments shared among plants, human animals, and

domestic, agricultural, and wild nonhuman animals. One Health is an approach that promotes national and international collaboration and coordinated responses to human population growth, agricultural encroachment and deforestation, ecosystem disruption, and interactions that intensify human-nonhuman animal transmission risks. Climate change diminishes biodiversity; diminished biodiversity undermines natural ecological balance dynamics between pathogens and hosts and has already influenced health care dramatically. This theme issue investigates the nature and scope of our collective responses to key changes.

From the Editor

[Emerging Infectious Diseases at the Intersections of Human, Animal, and Environmental Health](#)

Ariadne A. Nichol

Combatting infections that start in several species is neither practically nor ethically easy. AMA J Ethics. 2024;26(2):E99-102. doi: 10.1001/amajethics.2024.99.

Case and Commentary

[Which Factors Matter Most When Using Vaccines to Combat Zoonoses?](#)

Erica Kaufman West, MD

Zoonoses are infectious diseases that pass from an animal to a human and now constitute the majority of new and emerging infections.

AMA J Ethics. 2024;26(2):E103-108. doi: 10.1001/amajethics.2024.103.

Medicine and Society

[Can One Health Policy Help Us Expand an Ethics of Interconnection and Interdependence?](#)

Karen M. Meagher, PhD

Antimicrobial resistance demonstrates the fruitfulness of public health and bioethics collaborations by applying key concepts of interconnection and interdependence.

AMA J Ethics. 2024;26(2):E162-170. doi: 10.1001/amajethics.2024.162.

American Journal of Human Genetics

Feb 01, 2024 Volume 111 Issue 2p211-402

<https://www.cell.com/ajhg/current>

[This Month in The Journal](#)

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Human genetic variation influences susceptibility to infectious disease. Antibodies, stable biological markers of the response to infection, can be measured and leveraged to understand disease exposure, chronic infection state, and risk. Measured antibody titers in combination with genome-wide genotyping data can be used to identify common variants that influence both susceptibility and response to infectious disease. In this issue, Chong et al. perform a genome-wide association study of quantitative antibody responses to 45 antigens on the 9,611 individuals in the UK Biobank with both serology and imputed genetic data.

American Journal of Infection Control

February 2024 Volume 52 Issue 2 p141-260

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

American Journal of Preventive Medicine

February 2024 Volume 66 Issue 2 p195-388

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

February 2024 114(2)

<http://ajph.aphapublications.org/toc/ajph/current>

EDITORIALS

[Tuberculosis in US Indigenous Communities: A Need for Public Health Prioritization](#)

Lucia Cilloni and David W. Dowdy

[Vaccine Hesitancy, Pharmaceutical Marketing, and Mistrusted Messengers](#)

James Colgrove

OPEN-THEMED RESEARCH

[Racial and Ethnic Disaggregation of Tuberculosis Incidence and Risk Factors Among American Indian and Alaska Native Persons—United States, 2001–2020](#)

Yuri P. Springer, Thomas D. Filardo, Rachel S. Woodruff and Julie L. Self

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 2 (Feb 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-2.xml>

[New issue; No digest content identified]

Annals of Internal Medicine

January 2024 Volume 177, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmethics/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 10 Feb 2024)

[Exploring the reasons for defaulting from childhood immunization: a qualitative study in Pakistan](#)

Childhood vaccination is widely recognized as the most effective means to prevent various diseases. However, a considerable amount of children still miss out on their vaccination schedules. Therefore, this stu...

Authors: Kifayat Ullah, Javeria Saleem, Rubeena Zakar, Muhammad Ishaq, Farhad Ali Khattak, Fatima Majeed, Hafiza Aisha Sadiqa and Florian Fischer

Citation: BMC Public Health 2024 24:408

Content type: Research Published on: 8 February 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 10 Feb 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

BMJ Global Health

February 2024 - Volume 9 - 2

<https://gh.bmj.com/content/9/2>

Original research

[Enhanced or hindered research benefits? A realist review of community engagement and participatory research practices for non-communicable disease prevention in low- and middle-income countries](#) (10 February, 2024)

Sonja Klingberg, Bipin Adhikari, Catherine E Draper, Edna Bosire, Deborah Nyirenda, Priscilla Tiigah, Ferdinand C Mukumbang

[Assessing the effectiveness of the expanded hepatitis A vaccination program in China: an interrupted time series design](#) (6 February, 2024)

Yueqian Wu, Pengyu Wang, Yong Huang, Jinwei Chen, Yikun Chang, Junxi Li, Yibing Wang, Yuantao Hao, Wangjian Zhang, Zhicheng Du

Bulletin of the Atomic Scientists

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(2); 2024 Feb 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/454958/>

[Reviewed earlier]

Cell

Feb 01, 2024 Volume 187 Issue 3 p511-796

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Feb 01, 2024 Volume 187 Issue 3 p511-796

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 10 Feb 2024]

[No new digest content identified]

Contemporary Clinical Trials

Volume 137 February 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/137/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 2 2024

<https://www.tandfonline.com/toc/icmo20/current>

Vaccines - Article

[**The association between influenza vaccine effectiveness and egg-based manufacturing technology: literature review and US expert consensus**](#)

Archana Chatterjee, Karita Ambrose, David H. Canaday, Shirley Delair, Ngozi Ezike, Victor C. Huber, Ravi Jhaveri, Ann-Christine Nyquist, Abigail Sporer, Meera Varman, Renuga Vivekanandan, Radek Wojcik & Ravi Jandhyala

Pages: 335-343

Published online: 24 Jan 2024

Current Opinion in Infectious Diseases

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 10 Feb 2024]

[No new digest content identified]

Developing World Bioethics

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

ORIGINAL ARTICLES

[Reviewed earlier]

Development in Practice

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

Original Research

[How Do Past Immunization Strategies Compare With the COVID-19 Immunization Rollout: A New Zealand Analysis](#)

Emma Anderson, Elizabeth Fenton, Patricia Priest, Trudy Sullivan

Published online by Cambridge University Press:

08 February 2024, e18

Disasters

Volume 48, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/1>

[New issue; No digest content identified]

EMBO Reports

Volume 25 Issue 1 12 January 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

• *Local context and emergency research* • *Participant fraud in online research*
Passing demands in autism research :: Women missing in phase I trials

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

January/February 2024 Volume 103, Number 1

<https://www.foreignaffairs.com/issues/2023/103/1>

[Reviewed earlier]

Forum for Development Studies

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 1 January 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/2>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 10 Feb 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 11, No. 6 December 22, 2023

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 10 Feb 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 10 Feb 2024]

[Vaccine hesitancy and equity: lessons learned from the past and how they affect the COVID-19 countermeasure in Indonesia](#)

Indonesia has made progress in increasing vaccine coverage, but equitable access remains challenging, especially in remote areas. Despite including vaccines in the National Immunization Program (NIP), coverage...

Authors: Rano K. Sinuraya, Rina F. Nuwarda, Maarten J. Postma and Auliya A. Suwantika

Citation: Globalization and Health 2024 20:11

Content type: Review Published on: 6 February 2024

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

SPECIAL ISSUE: On the roof top of health policy change

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 10 Feb 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 1-2 / January 2024

<https://www.liebertpub.com/toc/hum/35/1-2>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Jan 09, 2024 Volume 57 Issue 1 p1-192

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 10 Feb 2024]
[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 10 Feb 2024]
[No new digest content identified]

International Health

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 1 (2024): January 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/108>

[Reviewed earlier]

International Journal of Epidemiology

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 16 Issue 5 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/5>

Table of contents

[Reviewed earlier]

JAMA

February 6, 2024, Vol 331, No. 5, Pages 373-452

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Neonatal Outcomes After COVID-19 Vaccination in Pregnancy](#)

Mikael Norman, MD, PhD; Maria C. Magnus, PhD; Jonas Söderling, PhD; et al.

free access

JAMA. 2024;331(5):396-407. doi:10.1001/jama.2023.26945

This cohort study evaluates the risks of neonatal adverse events after exposure to COVID-19 vaccination during pregnancy.

[Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years](#)

Leora R. Feldstein, PhD; Amadea Britton, MD; Lauren Grant, MS; et al.

free access has audio

JAMA. 2024;331(5):408-416. doi:10.1001/jama.2023.27022

This study uses data from 3 prospective cohort studies conducted in the US to assess vaccine effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.

Viewpoint

[Lessons From the Mpox Response](#)

Demetre Daskalakis, MD, MPH; Nikki Romanik, MD; Ashish K. Jha, MD, MPH

JAMA. 2024;331(5):387-388. doi:10.1001/jama.2023.27868

This Viewpoint discusses 3 key lessons from the mpox response that can help better manage infectious disease outbreaks in the future.

JAMA Health Forum

February 2024, Vol 5, No. 2

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

February 2024, Vol 178, No. 2, Pages 104-208

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Editorial

[Influenza Vaccination in Pregnancy—Rolling Up Sleeves for Pregnant Persons and Infants](#)

Matthew J. Zuber, MD; April Miller, MD, MPH; Katherine A. Poehling, MD, MPH

[Maternal Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department Visits in Infants](#)

Leila C. Sahni, PhD, MPH; Samantha M. Olson, MPH; Natasha B. Halasa, MD, MPH; et al.

JAMA Pediatr. 2024;178(2):176-184. doi:10.1001/jamapediatrics.2023.5639

This case-control study evaluates the effectiveness of maternal vaccination against influenza during pregnancy in reducing rates of hospitalization and emergency department visits in infants younger than 6 months.

[Trends in HPV Vaccination Before Age 13 Years in the US National Immunization Survey—Teen](#)

Jodie L. White, MHS; M. Kate Grabowski, PhD; Thomas C. Quinn, MD, MSc; et al.

has audio

JAMA Pediatr. 2024;178(2):203-205. doi:10.1001/jamapediatrics.2023.5238

This survey study uses data from the National Immunization Survey—Teen to examine human papillomavirus (HPV) vaccination rates in adolescents aged 13 to 17 years, including rates of series completion before age 13 years.

JBI Evidence Synthesis

January 2024 - Volume 22 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2024 Volume 74 Issue 3 p395-628

<https://www.jahonline.org/current>

[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

February 2024 - Volume 50 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

February 2024 Volume 21 Issue 211

<https://royalsocietypublishing.org/toc/rsif/current>

Life Sciences–Mathematics interface

Research articles

[Ethical dilemma arises from optimizing interventions for epidemics in heterogeneous populations](#)

[Pratyush K. Kollepara](#), [Rebecca H. Chisholm](#), [István Z. Kiss](#) and [Joel C. Miller](#)

Published:07 February 2024Article ID:20230612

<https://doi.org/10.1098/rsif.2023.0612>

Abstract

Interventions to mitigate the spread of infectious diseases, while succeeding in their goal, have economic and social costs associated with them. These limit the duration and intensity of the interventions. We study a class of interventions which reduce the reproduction number and find the optimal strength of the intervention which minimizes the final epidemic size for an immunity inducing infection. The intervention works by eliminating the overshoot part of an epidemic, and avoids a second wave of infections. We extend the framework by considering a heterogeneous population and find that the optimal intervention can pose an ethical dilemma for decision and policymakers. This ethical dilemma is shown to be analogous to the trolley problem. We apply this optimization strategy to real-world contact data and case fatality rates from three pandemics to underline the importance of this ethical dilemma in real-world scenarios.

Journal of Travel Medicine

Volume 31, Issue 1, January 2024

<https://academic.oup.com/jtm/issue>

Editor's Choice

[WHO Strategic Advisory Group of Experts on Immunization recommendations for use of a novel pentavalent meningococcal ACWXY vaccine: a critical step towards ending meningococcal epidemics in Africa](#)

Lucy A McNamara and John Neatherlin

Journal of Travel Medicine, Volume 31, Issue 1, January 2024, taae002,

<https://doi.org/10.1093/jtm/taae002>

A new pentavalent meningococcal ACWXY vaccine is poised to have a dramatic impact on the burden of meningococcal disease in the meningitis belt of Africa. Implementation of this vaccine is a critical step towards the first visionary goal of WHO's roadmap to defeat meningitis by 2030: eliminating bacterial meningitis epidemics.

Editor's Choice

[Refugees and migrants at the heart of the synergies between universal health coverage, health security and health promotion](#)

Saverio Bellizzi and Santino Severoni

Journal of Travel Medicine, Volume 31, Issue 1, January 2024, taad137,

<https://doi.org/10.1093/jtm/taad137>

Responding to the health need of refugees and migrants is key to accommodate universal health coverage, health security and health promotion to guarantee the well-being and protection of populations. This is in line with the human rights agenda as well as with the adoption of a coherent efficient comprehensive health system.

Journal of Virology

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Feb 10, 2024 Volume 403 Number 10426 p503-586

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

[Malaria vaccines: a test for global health](#)

The Lancet

[Excerpt]

Throughout recorded history, malaria has blighted populations across the globe. Today, by far, WHO's African region has the highest burden. In 2022, the region was home to 233 million (94%) malaria cases and 580 000 (95%) malaria deaths, about 80% of which were in children younger than 5 years. Despite ambitions to reduce this burden, efforts to control malaria have stagnated: global cases dropped by 29% between 2000 and 2019 but only by 2% between 2015 and 2019. Might this all be about to change? On Jan 22, 2024, Cameroon began the roll-out of RTS,S/AS01, the first malaria vaccine to be used in a national immunisation programme. On Dec 21, 2023, WHO prequalified a second vaccine, R21/Matrix-M. Together, they raise fresh hopes for malaria control...

...The UN's Sustainable Development Goal target 3.3 aims for a 90% reduction in malaria incidence and mortality by 2030, and malaria elimination in at least 35 endemic countries. The roll-out of RTS,S/AS01 and the prequalification of R21/Matrix-M are pivotal moments for achieving these targets, not to mention in child health and the history of medicine more broadly. They are also a serious test of the ability of global institutions to work effectively with countries. Gavi has a new CEO, Sania Nishtar, a respected leader in global health. The organisation now faces its first major challenge under her leadership.

Comment

Malaria vaccines for children: and now there are two

Vasee Moorthy, Mary J Hamel, Peter G Smith

Scientific advisory councils in the COVID-19 response

Jean-François Delfraissy, et al. on behalf of Covid-19 National Scientific Advisory Councils: Presidents or Representatives

Articles

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Mehreen S Dattoo, et al. for the R21/Matrix-M Phase 3 Trial Group
Open Access

Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales

The HDR UK COALESCE Consortium

Therapeutic Review

A new age of precision gene therapy

Axel Schambach, et al.

Summary

Gene therapy has become a clinical reality as market-approved advanced therapy medicinal products for the treatment of distinct monogenetic diseases and B-cell malignancies. This Therapeutic Review aims to explain how progress in genome editing technologies offers the possibility to expand both therapeutic options and the types of diseases that will become treatable. To frame these impressive advances in the context of modern medicine, we incorporate examples from human clinical trials into our discussion on how genome editing will complement currently available strategies in gene therapy, which still mainly rely on gene addition strategies. Furthermore, safety considerations and ethical implications, including the issue of accessibility, are addressed as these crucial parameters will define the impact that gene therapy in general and genome editing in particular will have on how we treat patients in the near future.

Viewpoint

Population screening requires robust evidence—genomics is no exception

Clare Turnbull, et al

New genomic technologies have improved the speed and accuracy with which rare disease diagnoses can be made in individuals presenting with a phenotype. These advancements have led to enthusiasm for applying these technologies at the population level to identify individuals at increased genomic risk of disease, and for their application in common as well as rare diseases. The UK has seen two major initiatives launch in 2023 that explore population screening by use of genomics. In the Genomics England Newborn Genomes Programme (NGP; the Generations Study), actionable findings from whole-genome sequencing (WGS) will be communicated for more than 200 diseases in 100 000 participating newborn babies.¹ The UK's Our Future Health (OFH) programme is recruiting up to 5 million adults via the National Health Service (NHS) for participation in research on common genetic variants, with plans to provide feedback to participants on their genomic risk of developing a range of common diseases.

The Lancet Child & Adolescent Health

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jan 2024 Volume 6 Number 1 e1-e86

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Jan 2024 Volume 24 Number 1 p1-106, e1-e69

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Jan 2024 Volume 9 Number 1 e1-e67

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Jan 2024 Volume 12 Number 1 p1-88

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 1, January 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jan 03, 2024 Volume 32 Issue 1 p1-260

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 626 Issue 7998, 8 February 2024

<https://www.nature.com/nature/volumes/625/issues/7998>

Editorial 06 Feb 2024

Open science — embrace it before it's too late

A UNESCO report laments the lack of progress in making science more collaborative. Greater awareness could aid efforts to achieve the UN's Sustainable Development Goals.

Nature Biotechnology

Volume 42 Issue 1, January 2024

<https://www.nature.com/nbt/volumes/42/issues/1>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 10 Feb 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 1, January 2024

<https://www.nature.com/ng/volumes/56/issues/1>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 1, January 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/1>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 1, January 2024

<https://www.nature.com/nm/volumes/30/issues/1>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 1, January 2024

<https://www.nature.com/nrd/volumes/23/issues/1>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 1, January 2024

<https://www.nature.com/nri/volumes/24/issues/1>

[Reviewed earlier]

New England Journal of Medicine

February 8, 2024 Vol. 390 No. 6

<https://www.nejm.org/toc/nejm/medical-journal>

Perspective

The Risks of Normalizing Parental Vaccine Hesitancy

D.M. Higgins and S.T. O'Leary

Advanced HIV as a Neglected Disease

N. Ford, P. Ehrenkranz, and J. Jarvis

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 10 Feb 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 2 February 2024

<https://publications.aap.org/pediatrics/issue/153/2>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 2 February 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-2>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 10 Feb 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 10 Feb 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 10 Feb 2024)

[One billion doses and WHO prequalification of nOPV2: Implications for the global polio situation and beyond](#)

Ananda S. Bandyopadhyay, Laura V. Cooper, Simona Zipursky

Opinion | published 09 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002920>

[Conflicts in Gaza and around the world create a perfect storm for infectious disease outbreaks](#)

John E. Kearney, Natalie Thiel, Arian El-Taher, Sabreen Akhter, David A. Townes, Indi Trehan, Paul S. Pottinger

Opinion | published 07 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002927>

[Trends of non-vaccination, under-vaccination and missed opportunities for vaccination \(2003–2014\) amongst children 0–23 months in Kenya](#)

Christopher Ochieng' Odero, Doreen Othero, Vincent Omondi Were, Collins Ouma

Research Article | published 06 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002906>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 10 Feb 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 10 Feb 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 10 Feb 2024]

[Understanding COVID-19 vaccination behaviors and intentions in Ghana: A Behavioral Insights \(BI\) study](#)

Swathi Vepachedu, Anastasiia Nurzenska, Anna-Leena Lohiniva, Al-hassan Hudi, Sena Deku,

Julianne Birungi, Karen Greiner, Joseph Sherlock, Chelsi Campbell, Lori Foster

Research Article | published 09 Feb 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0292532>

[High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study](#)

María Inés Sarmiento-Medina, Miryam Puerto de Amaya, Licet Villamizar-Gómez, Andrea Carolina González-Coba, Laura Guzmán-Barajas

Research Article | published 05 Feb 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0297579>

[Testing the cultural-invariance hypothesis: A global analysis of the relationship between scientific knowledge and attitudes to science](#)

Patrick Sturgis, Ian Brunton-Smith, Nick Allum, Simon Fuglsang
Research Article | published 05 Feb 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0296860>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 10 Feb 2024]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

February 6, 2024 vol. 121 no. 6
<https://www.pnas.org/toc/pnas/121/6>
[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 1, January 2024
<https://academic.oup.com/pnasnexus/issue/3/1>
[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 38 - Issue 6 - December 2023
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 178 January 2024
<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

31 January 2024 Volume 291 Issue 2015
<https://royalsocietypublishing.org/toc/rspb/current>
[Reviewed earlier]

Public Health

Volume 226 Pages e1-e6, 1-274 (January 2024)
<https://www.sciencedirect.com/journal/public-health/vol/226/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

Original Articles

[How to Design Consent for Health Data Research? An Analysis of Arguments of Solidarity](#)

Svenja Wiertz

Public Health Ethics, Volume 16, Issue 3, November 2023, Pages 261–270,

<https://doi.org/10.1093/phe/phad025>

The article discusses the impact different concepts of solidarity can have on debates on models of consent for non-interventional research. It introduces three concepts of solidarity that have been referenced in bioethical debates: a purely descriptive concept, a concept that claims some derivative value for most but not all practices of solidarity, as well as a clearly normative concept where solidarity is tied to justice and taken to ground moral duties. It shows that regarding the rivalling models of study-specific consent, tiered consent and broad consent, the first two concepts can be taken to favour tiered consent while only normative solidarity supports a model of broad consent—or an argument to allow non-interventional research without requiring consent at all. As normative solidarity is tied to considerations of justice, however, the argument appears less straightforward than one might expect: It presupposes that the research contributes to overcoming existing social injustices.

Public Health Genomics

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 10 Feb 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[Reviewed earlier]

Risk Analysis

Volume 44, Issue 2 Pages: 281-507 February 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

ORIGINAL ARTICLES

[Ingroup favoritism on perceived risk of infectious diseases](#)

Mei Peng, Xuejun Bai

Pages: 285-294

First Published: 20 June 2023

[Comparative risk perception of the monkeypox outbreak and the monkeypox vaccine](#)

Janet Z. Yang

Pages: 295-303

First Published: 28 April 2023

[Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences](#)

Dominika A. Kalkowska, Steven G. F. Wassilak, Eric Wiesen, Cara C. Burns, Mark A. Pallansch, Kamran Adelaidean, Kimberly M. Thompson

Pages: 366-378

First Published: 21 June 2023

[Worst-case scenarios: Modeling uncontrolled type 2 polio transmission](#)

Dominika A. Kalkowska, Eric Wiesen, Steven G. F. Wassilak, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan, Kimberly M. Thompson

Pages: 379-389

First Published: 21 June 2023

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 10 Feb 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6683| 9 Feb 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 1 February 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-1>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 733| 7 Feb 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 10 Feb 2024]

[No new digest content identified]

Social Science & Medicine

Volume 340 January 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/340/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 10 Feb 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 4 Pages 723-994 (6 February 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/4>

Research article Abstract only

[National vaccination policies for health workers – A cross-sectional global overview](#)

Stacy Young, Shoshanna Goldin, Laure Dumolard, Stephanie Shendale, ... Shalini Desai

Pages 757-769

Research article Abstract only

[Expanding polio surveillance reach beyond vaccination reach in Borno State, Nigeria: The contribution of community informants from insecure areas engaged to conduct polio surveillance in security compromised areas, 2018–2019](#)

Abede Momoh Mohammed, Audu Musa, Sume Gerald Etapelong, Mohammed Tahir Bolori, ... Walter Kazadi Mulombo
Pages 770-776

Research article Open access

[Trends in childhood vaccination in Pakistan and associated factors; 2006–2018](#)

Grace E. Joachim, Abram L. Wagner, Mustafa Naseem, Matthew L. Boulton
Pages 795-800

Research article Open access

[Influence of the COVID-19 pandemic on caregiver beliefs and experiences of routine childhood immunisation in Indonesia](#)

Madeleine Randell, Meru Sheel, Michelle Dynes, Mu Li, ... Tri Yunis Miko Wahyono
Pages 812-818

Research article Abstract only

[Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine \(IPV\) in routine immunization](#)

Kimberly M. Thompson, Dominika A. Kalkowska, Sarah E. Kidd, Cara C. Burns, Kamran Badizadegan
Pages 819-827

Research article Abstract only

[Can endorsement by religious leaders move the needle on vaccine hesitancy?](#)

Allen Hicken, Pauline Jones, Anil Menon, Laura S. Rozek
Pages 918-923

Brighton Collaboration papers

Research article Open access

[Benefit-risk assessment of vaccines](#)

Sonali Kochhar, Hector S. Izurieta, Rebecca E. Chandler, Adam Hacker, ... Bennett Levitan
Pages 969-971

Research article Open access

[The Brighton collaboration standardized module for vaccine benefit-risk assessment](#)

Bennett Levitan, Stephen C. Hadler, William Hurst, Hector S. Izurieta, ... Sonali Kochhar
Pages 972-98

Abstract

Vaccine Benefit-Risk (B-R) assessment consists of evaluating the benefits and risks of a vaccine and making a judgment whether the expected key benefits outweigh the potential key risks associated with its expected use. B-R supports regulatory and public health decision-making throughout the vaccine's lifecycle. In August 2021, the Brighton Collaboration's Benefit-Risk Assessment of Vaccines by Technology (BRAVATO) Benefit-Risk Assessment Module working group was established to develop a standard module to support the planning, conduct and evaluation of structured B-R assessments for vaccines from different platforms, based on data from clinical trials, post-marketing studies and real-world evidence. It enables sharing of relevant information via value trees, effects tables and graphical depictions of B-R trade-offs. It is intended to support vaccine developers, funders, regulators and policy makers in high-, middle- or low-income countries to help inform decision-making and facilitate transparent communication concerning development, licensure, deployment and other lifecycle decisions.

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 10 Feb 2024]

Latest Articles [Selected]

Open Access Article

[COVID-19 Vaccinations, Trust, and Vaccination Decisions within the Refugee Community of Calgary, Canada](#)

by [Fariba Aghajafari](#), et al.

Vaccines 2024, 12(2), 177; <https://doi.org/10.3390/vaccines12020177> - 09 Feb 2024

Abstract

Refugee decisions to vaccinate for COVID-19 are a complex interplay of factors which include individual perceptions, access barriers, trust, and COVID-19 specific factors, which contribute to lower vaccine uptake. To address this, the WHO calls for localized solutions to increase COVID-19 vaccine uptake...

Value in Health

February 2024 Volume 27 Issue 2 p133-270

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 10 Feb 2024]

Selected Research

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 10 Feb 2024]

[Filter: All articles]

[Pre-vaccination carriage prevalence of Streptococcus pneumoniae serotypes among internally displaced people in Somaliland](#)

Kevin van Zandvoort, Abdirahman Ibrahim Hassan, Mohamed Bobe, Casey L Pell, Mohamed Saed Ahmed, Belinda D Ortika, Saed Ibrahim, Mohamed Ismail Abdi, Mustapha A Karim, Rosalind M Eggo, Sulieman Yusuf, Jason Hinds, Saed Mohamood Soleman, Rachael Cummings, Catherine McGowan, Kim Mulholland, Mohamed Abdi Hergeeye, Catherine Satzke, Francesco Checchi, Stefan Flasche
medRxiv 2024.02.09.24302568; doi: <https://doi.org/10.1101/2024.02.09.24302568>

[Influenza vaccination allocation in tropical settings under constrained resources](#)

Joseph L Servadio, Marc Choisy, Pham Quang Thai, Maciej F Boni
medRxiv 2024.02.08.24302551; doi: <https://doi.org/10.1101/2024.02.08.24302551>

Abstract

Influenza virus seasonality, synchronicity, and vaccine supply differ substantially between temperate and tropical settings, and optimal vaccination strategy may differ on this basis. Most national vaccine recommendations focus on high-risk groups, elderly populations, and healthcare workers despite previous analyses demonstrating broad benefits to vaccinating younger high-contact age groups. Here, we parameterized an age-structured non-seasonal asynchronous epidemiological model of influenza virus transmission for a tropical low-income setting. We evaluated timing and age allocation of vaccines across vaccine supplies ranging from 10% to 90% using decade-based age groups. Year-round vaccination was beneficial when comparing to vaccination strategies focused on a particular time of year. When targeting a single age-group for vaccine prioritization, maximum vaccine allocation to the 10-19 high-contact age group minimized annual influenza mortality for all but one vaccine supply. When evaluating across all possible age allocations, optimal strategies always allocated a plurality of vaccines to school-age children (10-19). The converse however was not true as not all strategies allocating a plurality to children aged 10-19 minimized mortality. Allocating a high proportion of vaccine supply to the 10-19 age group is necessary but not sufficient to minimize annual mortality as distribution of remaining vaccine doses to other age groups also needs to be optimized. Strategies focusing on indirect benefits (vaccinating children) showed higher variance in mortality outcomes than strategies focusing on direct benefits (vaccinating the elderly). However, the indirect benefit approaches showed lower mean mortality and lower minimum mortality than vaccination focused on the elderly.

[Quantifying the Risk of Conflict on Recent Ebola Outbreaks in Guinea and the Democratic Republic of the Congo](#)

Gina E C Charnley, Nathan Green, Ilan Kelman, Espoir B Malembaka, Katy A M Gaythorpe
medRxiv 2023.05.30.23290713; doi: <https://doi.org/10.1101/2023.05.30.23290713> Revision

[Pathogen genomics and One Health: a scoping review of current practices in zoonotic disease research](#)

Stefano Catalano, Francesca Battelli, Zoumana I Traore, Jayna Raghwan, Christina L Faust, Claire J Standley

medRxiv 2024.02.05.24302264; doi: <https://doi.org/10.1101/2024.02.05.24302264>

ABSTRACT

Whole-genome sequencing has revolutionised the field of infectious disease surveillance, enabling near real-time detection of pathogens and tracking how infections may spread. We performed a scoping review of studies that have applied genomic epidemiology to zoonotic disease transmission across One Health domains (human, animal, and environment). We identified 114 records published between 2005 and 2022 which reported original multi-domain genomic data of zoonotic pathogens integrated into phylogenetic models. Most studies investigated bacterial pathogens, highlighting key knowledge gaps for other zoonotic agents, particularly arboviruses. Sampling and sequencing efforts vastly varied across domains: the median number and range of pathogen genomes analysed were highest for humans (23; 1-29,586) and lowest for the environment domain (13; 1-956). Infectious

disease genomics was leveraged to track zoonotic disease outbreaks and cross-domain transmission, to enhance pathogen surveillance, and to disentangle evolutionary dynamics driving lineage diversification and virulence. Our study informs effective study design for future genomic applications to multi-domain and cross-species transmission of zoonoses, with the potential to identify key infection sources and inform interventions for local and global health security.

Funding Statement

SC, FB, ZIT, and CJS were sponsored by the Defense Threat Reduction Agency, United States Department of the Defense (HDTRA12110028). The content of the information does not necessarily reflect the position or the policy of the federal government, and no official endorsement should be inferred. CLF was supported by a Natural Environment Research Council Independent Research Fellowship (NE/V01430/1). JR was supported by the UK Research and Innovation Global Challenges Research Fund One Health Poultry Hub (BB/S011269/1).

[Inequalities in childhood vaccine uptake: a longitudinal analysis of national coverage in England 2019-23](#)

Aidan Flatt, Roberto Vivancos, Neil French, Sophie Quinn, Matthew Ashton, Valérie Decraene, Daniel Hungerford, David Taylor-Robinson
medRxiv 2024.02.03.24301936; doi: <https://doi.org/10.1101/2024.02.03.24301936>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 10 Feb 2024]

Selected Research

[No new digest content identified]

* * * *

[Think Tanks](#)

Brookings [to 10 Feb 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 10 Feb 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 10 Feb 2024]

<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [to 10 Feb 2024]

<https://www.cfr.org/media/news-releases>
New Releases [Selected]
No new digest content identified.

CSIS [to 10 Feb 2024]

<https://www.csis.org/>
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 10 Feb 2024]

https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 10 Feb 2024]

<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 10 Feb 2024]

<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 10 Feb 2024]

<https://www.pewresearch.org/>
Latest Publications [Selected]
News

short reads | Feb 5, 2024

[8 charts on technology use around the world](#)

In most countries surveyed, around nine-in-ten or more adults are online. In South Korea, 99% of adults use the internet.

Rand [to 10 Feb 2024]

<https://www.rand.org/pubs.html>
Published Research [Selected]
Journal Article

[Predicting COVID-19 Outbreaks in Correctional Facilities Using Machine Learning](#)

Using machine learning methods with data collected from 24 prison facilities in the Pennsylvania Department of Corrections, we determine which sources of data best predict a coming COVID-19 outbreak in a prison facility.

Feb 7, 2024

Giovanni Malloy, Lisa B. Puglisi, Kristofer B. Bucklen, Tyler D. Harvey, Emily Wang, Margaret L. Brandeau

Urban Institute [to 10 Feb 2024]

<https://www.urban.org/publications>

New Research Publications - Selected

World Economic Forum [to 10 Feb 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

Call for Papers: Establishing the impact of WHO's normative and standard-setting functions: a call for papers

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

The deadline for submissions is 1 March 2024

Editorial

Lisa M Askie^a, Rebekah AL Thomas^a, Rok Ho Kim^a, Mubashar Sheikh^a, Jeremy Farrar^b

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization's (WHO) mandate, as outlined in its founding principles.¹ This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.² WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,⁶ the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO's credibility and impact as a normative organization. Questions remain as to how successful WHO's normative leadership role has been, how it can be further strengthened and how the impact of WHO's work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO's normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO's global normative leadership role during the pandemic,⁷ and looking to prepare for future threats such as the health effects of climate change and ongoing

conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO's mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO's normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization's mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *

*

*

*

*